Search Within

Hani Hassoun

Formats
  1. Meeting Abstract (232)
  2. Journal Article (90)
  3. Research Letter (9)
  4. Correspondence (4)
  5. Book Section (2)
  6. Review (2)
Groups
  1. Center for Hematologic Malignancies (339)
  2. Department of Medicine (339)
  3. Hematologic Malignancies, Division of (339)
  4. Myeloma (339)
  5. Survivorship Research (253)
  6. Bone Marrow Transplant (241)

More Groups

People
  1. Heather Landau (224)
  2. Sergio Giralt (205)
  3. Alexander Lesokhin (202)
  4. David Chung (166)
  5. Neha Korde (166)
  6. Sham Mailankody (163)

More People

Years
  1. 2025 (7)
  2. 2024 (35)
  3. 2023 (37)
  4. 2022 (36)
  5. 2021 (21)
  6. 2020 (28)

More Years

Publications
  1. Blood (133)
  2. Clinical Lymphoma, Myeloma and Leukemia (51)
  3. Journal of Clinical Oncology (27)
  4. Biology of Blood and Marrow Transplantation (19)
  5. Leukemia and Lymphoma (14)
  6. American Journal of Hematology (10)

More Publications

Publishers
  1. American Society of Hematology (141)
  2. Elsevier Inc. (74)
  3. American Society of Clinical Oncology (27)
  4. Nature Publishing Group (24)
  5. Taylor & Francis Group (21)
  6. John Wiley & Sons, Inc. (10)

More Publishers

Results (339)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rational targets in systemic AL amyloidosis
    Meeting Abstract

    Bal, S.; Dogan, A.; Hassoun, H.; Mailankody, S.; Giralt, S. A.; Landau, H. J.
    Blood (2021)

    Fulltext@MSK | Save
  • Melflufén más dexametasona en pacientes con mieloma múltiple recidivante/resistente (MMRR) con exposición/resistencia previa a agentes alquilantes: Análisis conjunto de los estudios O-12-M1 y HORIZON
    Meeting Abstract

    Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Bladé, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies
    Meeting Abstract

    Rodríguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol
    Meeting Abstract

    Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Providing nutritional guidance for patients with plasma cell disorders - A missed opportunity for hematologists and oncologists?
    Meeting Abstract

    Sweeney, N.; Malik, M.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P.; Mailankody, S.; Korde, N.; Tan, C.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in 55 patients with relapsed/refractory multiple myeloma with extramedullary disease-subgroup analysis
    Meeting Abstract

    Richardson, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma exposed and/or refractory to prior alkylators - A pooled analysis of the O-12-M1 and HORIZON studies
    Meeting Abstract

    Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J.; Hassoun, H.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) exposed or refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies
    Meeting Abstract

    Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save